基本介紹
- 中文名：謝新華
- 畢業院校：中山大學
- 學歷：博士研究生
- 職務：碩士生導師
專業方向,醫學專長,門診時間,社會任職,部分科研基金,代表性論文,
專業方向
乳腺外科
醫學專長
臨床手術技能：乳腺腫瘤的微創和腔鏡手術治療；乳腺癌改良根治術、保乳術及前哨淋巴結活檢術等；乳腺癌術後重建與整形修復。
科學研究方向：乳腺癌轉移和免疫調控的相關機制研究。
門診時間
周一上午（黃埔院區）、周二上午（越秀院區）、周四上午（越秀院區）
社會任職
廣東省抗癌協會乳腺癌專業委員會委員廣東省醫療行業協會乳腺專科管理分會委員
部分科研基金
1. 國家自然科學基金面上項目，81974444，2020/01-2023/12，51萬，主持；
2. 國家自然科學基金青年項目，81302318，2013.1-2016.12，23萬，主持；
3. 廣東省科技計畫項目， 2017A020215163，2017/01-2019/12, 10萬，主持。
代表性論文
1. N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nature Communication. 2022 05 13;13(1).
2. Incorporating miRNA into molecular phenotypes of circulating tumor cells enhances the prognostic accuracy for metastatic breast cancer patients. The Oncologist. 2019 Nov;24(11):e1044-e1054.
3. Metformin mediates induction of miR-708 to inhibit self-renewal and chemoresistance of breast cancer stem cells through targeting CD47. J Cell Mol Med. 2019.DOI:10.1111/jcmm.14462.
4. Nomogram to Predict Internal Mammary Lymph Nodes Metastasis in Patients With Breast Cancer. Front Oncol. 2019 Nov 8;9:1193.
5. Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling. Curr Cancer Drug Targets. 2018, 18, 1-8.
6. Adam12 and lnc015192 act as ceRNAs in breast cancer by regulating miR-34a. Oncogene. 2018 Jul 24.
7. Preoperative prediction nomogram based on primary tumor miRNAs signature and clinical-related features for axillary lymph node metastasis in early-stage invasive breast cancer. Int J Cancer. 2018, 142, 1901-1910.
8. Identification of a 4-mRNA metastasis-related prognostic signature for patients with breast cancer. J Cell Mol Med. 2018;1-13.
9. Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. Cancer Lett. 2015 Jan 28;356(2 Pt B):374-81.
10. Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models. Mol Cancer Ther. 2012 Sep;11(9):1915-24.
11. Targeted expression of E. coli purine nucleoside phosphorylase and Fludara for prostate cancer therapy. J Gene Med. 2011;13:680-691.
